Mixture of oligasaccharides

FIELD: food industry.

SUBSTANCE: method of oligasaccharide mixture production from animal milk which has the same range of oligasaccharides as milk it was produced from includes the following stages: (a) concentration of deproteines milk material to the total content of dry substance from 50 to 75% given the condition that temperature shall not rise to the level at which hydrolisis or sialic acid reduction take place; (b) concentrated milk is subject to partial lactose removal and preparation of solution with lactose: oligasaccharide ratio less than 250, and (c) demineralization of milk material - at this the stage of demineralization is conducted either before concentration stage or after lactose removal. Also invention refers to the mixture of oligasaccharides recieved this way from animal milk and food products containing the mentioned mixture of oligasaccharides.

EFFECT: receipt of mixture of oligasaccharides.

18 cl, 2 tbl, 3 ex

 

The technical field

The present invention relates to a mixture of oligosaccharides obtained from the milk of animals, to food products containing this mixture of oligosaccharides, and to a method for producing the above-mentioned mixture of oligosaccharides.

Prior art

In the human colon inhabits a wide range of bacteria that have both positive and negative effects on the physiology of the intestine, and other systemic effects. The predominant group of bacteria found in the colon include bacteroids (bacteria are saprophytes), bifidobacteria, eubacteria, clostridia and lactobacilli. Present bacteria are active, varying depending on the availability of substrate, redox potential, pH, partial pressure and distribution O2in the colon. In most cases, intestinal bacteria can be divided into species that have, or potentially harmful or beneficial effects on the body-master. The pathogenic effect (which may be caused, for example, Clostridium or bacteroids) include diarrhoea, infections, liver damage, carcinogenesis and putrefactive processes in the intestine. Healthy action may be due to the inhibition of the growth of harmful bacteria, stimulation of the immune f is NCCI, the digestion and absorption of essential nutrients and the synthesis of vitamins. Desirable is to increase the number and strengthen the activity of those groups of bacteria (such as bifidobacteria and lactobacilli), which have a stimulating health action.

Since we are talking specifically about breast children, it is assumed that the gastrointestinal tract of the child immediately before his birth is sterile. In the process of childbirth it is in contact with the bacteria of the digestive tract and the skin of the mother and begins to move them. There are significant differences in the composition of the intestinal microbiota in infants, due to their power. The faecal microflora in infants fed breast milk, characterized by the populations of bifidobacteria with some species of lactobacilli, while the infants fed formula milk have more complex microbiota, which are usually present all kinds of bifidus bacteria, bacteroids, Clostridium and Streptococcus spp. After weaning, the composition of the microbiota of the intestine gradually approaches the composition of the microbiota of an adult.

Breast milk is recommended for all infants. However, in some cases, breastfeeding is defective or adverse health while is to be either the mother herself refuses to breastfeed. For such situations mixture developed for infants.

One of the approaches to stimulate reproduction and/or activity of beneficial bacteria in the colon involves the addition of prebiotics in foods. A prebiotic is unassimilated food component that has beneficial effects on the body is the master of the fact that it selectively stimulates the growth and/or activity of one or a limited number of bacterial species in the colon and improves thereby the health of the host body. Such components are not assimilated in the sense that they do not split and is not absorbed in the stomach or small intestine, and are not undergoing changes in the colon where they are fermented selectively beneficial bacteria. Examples of prebiotics include some oligosaccharides, such as fructo-oligosaccharides (FOS) and galactooligosaccharides (GOS).

It is known that human milk contains an increased number of unassimilated oligosaccharides compared to the milk of most species. Actually unassimilated oligosaccharides are the third for the quantitative content of the solid component (after lactose and lipids in human milk, being present in a concentration of from 12 to 15 g/l in colostrum and from 5 to 8 g/l in Mature milk. Human milk oligosaccharides are very resistant to fermentation the mu hydrolysis, that indicates that these oligosaccharides can perform the essential functions does not depend directly on their caloric values.

As the study of the composition of breast milk were also invited to add prebiotics in infant formula for infants. Currently, the industry produces a different mix baby food with added prebiotics, such as, for example, a mixture of fructo-oligosaccharides and galactooligosaccharides. However, these compounds are only marginally closer to a mixture of oligosaccharides in human milk. In human milk are found more than 100 different oligosaccharide components, some of which have so far not detected in the milk of animals such as cow's milk, or found only in small quantities. Examples of classes of human milk oligosaccharides that are present in cow's milk and colostrum only in very small quantities or not present at all, are sililirovanie and fokusirovannyi oligosaccharides.

Application for U.S. patent No. 2003/0129278 describes the mixture of oligosaccharides on the basis of oligosaccharides, derived from the milk of one or more species, which differs in that it contains at least two oligosaccharide fractions, each of which consists of at least two different oligosaccharides is ri the absence of lactose. The broad spectrum of the oligosaccharides present in this mixture differs from the spectrum in the milk of one or more species of animals from which these oligosaccharide fractions were extracted. In addition, (a) if the oligosaccharides extracted from the milk of only one type of animal, the ratio of neutral to acid oligosaccharides (sililirovannymi) oligosaccharides is 90-60:10-40 wt.%, or (b) if the oligosaccharides extracted from milk, at least two species of animals, the oligosaccharides extracted from the milk of each of two different animal species, comprise 10 wt.% total amount of oligosaccharides present in a mixture of oligosaccharides.

U.S. patent No. 5270462 describes the method of extraction from cheese whey or rennet whey linked sialic acid oligosaccharides linked sialic acid peptides and associated sialic acid lipids at high concentration, which includes the stage of establishing the pH of the whey or rennet whey at pH 2-5; contacting the whey with a cation exchanger with getting passed through the cation exchanger of the solution and the concentration and/or desalting specified passed through the cation exchanger solution. The finished composition with a high content of sialic acids can the be used as raw materials or as medical raw materials.

EP 0458358 relates to a method for production of skimmed milk powder, containing 10-15 wt.% galactooligosaccharide, which includes:

(i) the concentration of skim milk with the production of concentrated milk solids content of 20-50 wt.%,

(ii) adding β-galactosidase to the concentrated milk in order to initiate the enzymatic reaction,

(iii) heating the resulting reaction mixture for from 30 seconds to 15 minutes to a temperature of 70-85°C to stop the enzymatic reaction and

(iv) spray drying the mixture after termination of the reaction.

The purpose of this invention is the provision of a mixture of oligosaccharides, which is effective as a prebiotic, in particular, in the human intestine, and which has oligosaccharide profile, more close to the same profile of breast milk than oligosaccharide profile provided by mixtures of fruits and vegetables galactooligosaccharides.

Summary of the invention

In one aspect the invention relates to a mixture of oligosaccharides obtained from the milk of animals, in which the mixture has a ratio of lactose:oligosaccharides of less than 250 and contains the same spectrum of oligosaccharides that the milk from which it was obtained. This component is a new protective and immunomodulatory component of that article is ucture closest to human milk oligosaccharides, for example, the fact that the relative content sililirovany oligosaccharides is higher compared to commercially available prebiotic components, such as fructo-oligosaccharides and galactooligosaccharides. Low ratio of lactose:oligosaccharides gives the advantage that the mixture of oligosaccharides may be added to infant formula for infants and other foods without the introduction of unnaturally high amounts of lactose. For example, 1 liter of infant formula can be added from 0.5 to 50 g of a mixture of oligosaccharides. Preferably, the mixture has a ratio of lactose:oligosaccharides from 125 to 1.25.

Preferably the mixture of oligosaccharides obtained from the milk of one or more species of animals - cow's milk, goat's milk or Buffalo milk, although you can use the milk of other animals such as sheep, camels, mares and female.

Optional mixture of oligosaccharides also contains β-galactooligosaccharide (β-GOS). Breast milk contains significantly more neutral oligosaccharides than animal milk such as cow's milk, which is why it is desirable to increase the content of GOS in a mixture of oligosaccharides according to the invention in order to obtain a mixture, which is closer to breast milk oligosaccharide profile. The ratio of oligosaccharide:β-galactooligosaccharide present in the mixture from which retene may be from 0.01 to 99. Preferably the ratio of OS:GOS is from 1:2 to 1:20, and particularly preferred is a ratio from 1:2 to 1:6.

In another aspect the invention relates to a food product containing a mixture of oligosaccharides described above. Optional food product is a product or formula for infants; it can be any food product or beverage for infants, older children or adults. The use of a food product containing a mixture of oligosaccharides as prebiotic, will selectively stimulate the growth and/or activity of one or a limited number of bacterial species in the colon, and to improve thereby the health of the host body.

The following aspect of the invention provides a method of obtaining a mixture of oligosaccharides from milk of animals that have the same range of oligosaccharides that the milk from which it was obtained, which includes the stages of (a) concentration deproteinizing milk material to the total solids content from 50 to 75%; (b) exposure to concentrated milk material stage removal of lactose from obtaining a solution in which the ratio of lactose:oligosaccharides is less than 250, and (C) demineralization of milk material, and the stage of demineralization is carried out either at the stage of concentrated the project, or after the stage of removal of lactose.

Preferably, stage (b) of the method includes a step of crystallization of lactose followed by a stage of concentration in order to remove the lactose crystals and a solution in which the ratio of lactose:oligosaccharides is less than 250.

Alternative stage removal of lactose may include spray drying the concentrated material obtained in stage (a), and subsequent addition of water to dissolve oligosaccharides with simultaneous removal of lactose in crystalline form.

The optional stage of crystallization and removal of lactose can be repeated (if a certain amount of lactose has already been removed by crystallization or additionally be entered (if it is on the difference in solubility) with the aim of further concentrating the solution and removal of lactose.

Preferably the stage of demineralization is carried out after stage (stages) remove lactose.

Preferably deproteinizing dairy material is an ultrafiltrate of milk or whey. However, you can use any deproteinizing dairy material, for example, acid whey or sweet whey (both of them are a by-product of cheese making), but in each case only after removing syvorotochnykh.

Optional method also includes processing of β-galactosidase to obtain β-galactooligosaccharides. Used β-galactosidase can be microbial, plant or animal origin, provided that it has a significant transglucosidase activity. Preferably used β-galactosidase from Aspergillus oryzae. Such enzymatic treatment may take place before concentrating deproteinizing dairy material or upon completion stages of removal of lactose or, if necessary, in both cases, but preferably it is conducted at the completion stages of removal of lactose.

After stage (stages) remove lactose liquid product can be processed by a separate proteases and/or their combinations with the aim of splitting the residual milk proteins and peptides to compounds with lower molecular weight. This is particularly preferable in the case, if the mixture of oligosaccharides must be entered in hypoallergenic infant formula baby food intended for infants with allergies to cow's milk and that for this reason only contain proteins, subjected to partial hydrolysis.

The liquid product may be applied in liquid form, but preferably it is subjected to spray drying to obtain a powder.

Young is a great description of the invention

The invention provides a mixture of oligosaccharides obtained from the milk of animals, in which the mixture has a ratio of lactose:oligosaccharides of less than 250, and contains the same spectrum of oligosaccharides that the milk from which it was obtained, and the method of obtaining the above-mentioned mixture. This mixture may be injected into food products for children or adults and to provide prebiotic, immunomodulatory and protective effects.

In the context of describing "oligosaccharide" is defined as the oligosaccharides contained on the nature of in-milk animals and having a degree of polymerization (DP) ranging from 3 to 20, inclusive.

The mixture of oligosaccharides according to the invention also contains lactose (DP=2) and has lactose:oligosaccharides of less than 250, preferably from 125 to 1.25. This corresponds to a reduction of the lactose content in the mixture of oligosaccharides 2-200 times compared to the original milk of animals, which is equivalent to improve the ratio between the oligosaccharides and lactose in 2-200 times.

The mixture of oligosaccharides according to the invention is obtained from the milk of one or more species of animals. Milk can be obtained from any species, particularly from cows, goats, Buffalo, mares, bulls, camels, or sheep.

The starting material in the method of obtaining a mixture of oligosaccharides is deproteinizing dairy material, such as milk,from which the deleted proteins, or whey or any processed or modified whey material from which removed whey proteins. Such materials include acid whey and sweet whey. Preferred raw materials are ultrafiltrate milk and serum ultrafiltrate. Alternative starting material can be recovered powder, for example, powdered ultrafiltrate.

The source material must be deproteinisation product, because the presence of proteins on the stage of concentration can lead to undesirable Maillard reactions and brown. The deproteinization of the source material can be carried out by any known means, for example by deposition of acids, thermal processes, ion exchange. However, it is preferable that the removal of the protein was carried out by ultrafiltration, in which the source material is removed and lipids.

Source material may be subjected to also demineralization by any known means, for example, reverse osmosis, nanofiltration or ion exchange. Alternative stage of demineralization may be performed after stage (stages) remove lactose, again using known means.

The pH of the source material can range from 3 to 7.5, although the pH from 5 to 6 is particularly preferred is entrusted, as helps prevent hydrolysis of oligosaccharides, for example, desialylation sialyllactose and risk reduction reactions Browning.

Deproteinizing dairy material is concentrated to a total solids content (TS) from 50 to 75%, preferably from 55 to 60% TS, by any known means, provided that the temperature does not rise to a level that can occur hydrolysis or desialylation oligosaccharides. The concentration is preferably carried out at temperatures from 50 to 90°C., more preferably from 50 to 75°C. Evaporation is one of the preferred methods, which is carried out at a pressure of from 80 to 200 mbar. In this way the temperature does not rise above 60°C, which guarantees the absence of harmful effects on oligosaccharides. Alternatively, if the source material is a powder, the concentration to the desired level can be achieved by the appropriate recovery powder.

The method includes optional additional step of processing deproteinizing dairy material β-galactosidase with getting milk material containing β-galactooligosaccharide (β-GOS). Dairy material may be processed by β-galactosidase in front of concentrated dairy material (stage (a)) and/or after stage (article is Dios) remove lactose (stage (b)), but preferably this treatment is conducted after the completion of stage (stages) remove lactose. β-galactosidase catalyzes the decomposition of lactose to the monosaccharides - galactose and glucose and the subsequent formation of galactooligosaccharides. Preferably used β-galactosidase produced by Aspergillus oryzae. This enzyme is released by the industry as Lactase F from the company Amano, Japan. The enzyme activity measured in accordance with the method of FCCIV (International production standard), may be from 1,000 to 30,000 units/kg of lactose. Processing enzyme may be carried out at a pH of from 3 to 8 and a temperature of from 4 to 70°C on the source material with the concentration of lactose from 5 to 70 g/100 g TS at a concentration of enzyme of from 1.5 to 10 g/kg of a mixture of oligosaccharides. Preferably use about 5 grams of enzyme per kg of the mixture of oligosaccharides, and incubation lasts from 1 to 24 hours at 40-70°C. After use, the enzyme can inaktivirovanie heat.

Preferably stage remove lactose is the crystallization of lactose. Crystallization of lactose can be carried out in concentrated source material by cooling the concentrated material with or without adding seed crystals, for example. Crystals of lactose then removed by any known method, for example by centrifugation, Phi is Tricia, by decantation.

An alternative method of separation of lactose from oligosaccharides based on the difference in solubility. The source material is subjected to spray drying, after which water is added to dissolve oligosaccharides with simultaneous removal of the crystallized lactose.

The resulting solution is rich in oligosaccharides, and the ratio of oligosaccharide:lactose in it 2-200 times higher than the ratio in the milk from which the above solution was obtained.

The solution may be re-concentration, as described above, and then may be the stage of removal of lactose. This process can be repeated many times as necessary.

After removal from the solution the required amount of lactose, it can be processed by a single protease and/or a combination of proteases, with the aim of splitting the residual milk proteins and peptides to compounds with lower molecular weight. This stage may be desirable if the mixture is intended for the introduction of hypoallergenic infant formula for infants.

The solution preferably is processed β-galactosidase with the formation of β-galactooligosaccharides, as described above. This allows to obtain a second estimated ingredient for food products containing Alyosha the IDA milk, defined above, and GOS with DP from 3 to 10.

After the processing of β-galactosidase in an amount of from 1 to 6 mg enzyme/g TS solution with a total concentration of solids of 50% and a lactose content of about 35% of the final solution may contain from about 2 to 4% of the oligosaccharides, from about 2 to 15% GOS, from about 15% to 30% lactose, about 5 to 10% galactose and about from 2 to 14% glucose. The ratio of oligosaccharide:β-GOS can vary from 0.01 to 99, but ranges from 1.2 to 1:20, more preferably from 1:2 to 1:6.

The resulting solution can be applied in liquid form or may be subjected to drying (e.g. spray drying) to obtain the powder. The finished powder contains about 50% lactose, the rest is a mixture of oligosaccharides (about 1 to 20%, including sililirovanie oligosaccharides, monosaccharides, such as glucose and galactose, about 10% of non-protein nitrogen compounds, 2% residual protein and some amount of residual salts.

In a preferred aspect of the invention a mixture of oligosaccharides described above, are introduced into the food product. In the context of the present invention, the term "food product" includes any usable substance. Therefore, it can be a product designed for human consumption, in particular milk formula for infants, dehydrated milk powders, including breast is haunted mixture for feeding infants older or a mixture of grains (cereals).

Milk formula for infants can be prepared in any suitable way. For example, milk formula for infants can be prepared by blending together the protein source, any carbohydrates, in addition to lactose, and source of fat taken in appropriate proportions. If necessary, can be added emulsifiers. At the same time can be added vitamins and minerals, but they are usually made later in order to prevent their collapse during the heat treatment. Before mixing the lipophilic vitamins, emulsifiers, etc. can be pre-dissolved in the source of fat. To obtain a liquid mixture can be added to water, preferably water, treated in terms of reverse osmosis.

The liquid mixture may be subjected to heat treatment to reduce bacterial load. For example, the liquid mixture may be subjected to rapid heating to a temperature of about from 80 to 110°C for about from 5 seconds to 5 minutes. This can be achieved by direct injection of steam or heat exchanger, for example in a plate heat exchanger.

Thereafter, the liquid mixture may be cooled to a temperature of from about 60 to 85°C., for example, by way of instant cooling. Then, the liquid mixture may be subjected to homogenization, for example, in two stages when gallerieporno from 7 to 40 MPa in the first stage and from about 2 to 14 MPa in the second stage. Gomogenizirovannogo the mixture can be subjected to subsequent cooling to add a heat-sensitive components, such as vitamins and minerals.

The pH value and the content of dry matter digested mixture is uniform at this stage.

Gomogenizirovannogo mixture is transported to the appropriate drying unit, for example, a spray drier or freeze drier, where it turns into powder. The powder should have a moisture content below about 5 wt.%

The mixture of oligosaccharides according to the invention may be added to infant formula for infants or other food product by wet mixing at an appropriate stage of the manufacturing process or by dry mixing, but preferably it is added by wet mixing immediately before spray drying, for example in a standardized tank. However, a qualified specialist in the art it is obvious that the amount of carbohydrate in milk formula for infants should be regulated taking into account the additional carbohydrates provided by a mixture of oligosaccharides. The final concentration of the mixture of oligosaccharides in food or formula for infants or infants should preferably be from 2 to 50 g/l, for example, 32,5g/l is fed to the mixture. However, these amounts should not be construed as limiting; they need to be adapted to the target audience, the power of which they are used, taking into account, for example, body mass and age or health status of the newborn or infant. Preferably the newborn in each feeding can be given infant formula containing a mixture of oligosaccharides according to the invention.

Alternative mixture of oligosaccharides can be added to foods for children or adults by dry mixing. The mixture may be added in the milk mixture for a newborn or infant in concentrations of from about 5 to 40 grams of oligosaccharides per 100 g of dry formula without the introduction of unnaturally high amounts of lactose in milk mixture. However, these amounts should not be construed as limiting; they need to be adapted to the target audience, the power of which they are used, taking into account, for example, body mass and age of a newborn or infant or health specific target audience.

While this mixture is preferably intended for introduction into the food supply purpose - nutrient mixture for newborns or infants, adding it may be useful in food products without ODA is divided by purpose, or products for an adult audience. For example, a mixture of oligosaccharides according to the invention may be introduced into the series products are "healthy eating and nutritional products for the elderly. Such foods can include milk, yogurt, curd, cheese, fermented milk drinks, fermented products based on milk, ice cream, fermented foods corn-based or product based on milk, along with other.

Below is the description of the invention with reference to the following examples.

Example 1

The following describes one method of preparing the mixture of oligosaccharides according to the invention.

200,000 liters of ultrafiltrate whey is subjected to a preliminary concentration to the total solids content (TS) 22% (wt./mass.), pasteurized at about 75°C for about 30 seconds, and then concentrated by evaporation at 60°C to TS 59% (wt./mass.). The liquid is cooled in the crystallizer at a rate of 2°C per hour for 24 hours for crystallization of lactose in it. Then crystallized lactose is removed by washing in squeezing the centrifuge. The remaining liquid lighten in the decanter-clarifier. Received in the decanter-Dodge 77,000 litres with TS 17.7% of re-concentrated by evaporation at 60°C before reaching the TS 55% (wt./mass.) and put the second study the crystallization of lactose under the same conditions, as in the first stage. Thus obtained 29,000 liters of solution with TS 20,5% demineralized known per se combined method of electrodialysis and ion exchange with access 28500 liters of demineralized 90% solution with TS to 17.3%. This solution, which contains about 2 grams of milk oligosaccharides animals per 100 g TS and 70 grams of lactose per 100 g TS, can be added directly to a food product, such as milk formula for infants, in the form of a wet phase, or can be subjected to drying, for example spray drying, and then add to a food product, such as milk formula for infants, a dry mixing method.

Example 2

100 kg of a mixture of oligosaccharides obtained according to example 1, with TS 50% heated to 60°C in a standard tank and set its pH level of 6-6 .5. Measured concentrations of lactose, glucose, galactose, galactooligosaccharides and other oligosaccharides in the mixture. Add 4.5 mg of the finished product lactase Lactase F (Amano, Japan) for each g TS, and the total mixture was incubated at 60°C for three hours. Then the temperature was raised to 110°C. for 11 seconds by direct injection of steam with the purpose of inaktivirovanie enzyme. Re-measure the concentrations of lactose, glucose, galactose, galactooligosaccharides and other oligosaccharides in the mixture. The measurement results are given below.

(% dry matter)LactoseGlucoseGalactoseOSGOS
At time 0703520,7
After 3 hours291211210

Example 3

An example of the composition of formula for infants containing a mixture of oligosaccharides according to the present invention, is described below.

tr>
Nutrient100 kcal1 liter
Energy value (kcal)100670
Protein (g)1,8312,3
Fat (g)5,335,7
Linoleic acid (g)0,795,3
α-linolenic acid (mg)101675
Lactose (g)11,274,7
OS mixture (example 1) (g)1,491,0
GOS (from example 2) (g)0,7465,0
Minerals (g)0,372,5
Na (mg)23150
K (mg)89590
Cl(mg)64430
Ca (mg)62410
P (mg)31210
Mg (mg)750
MP (g)850
Se (µg)213
Vitamin A (µg RE) 105700
Vitamin D (µg)1,510
Vitamin E (mg TE)0,8of 5.4
Vitamin K1 (μg)854
Vitamin C (mg)1067
Vitamin B1 (mg)0,070,47
Vitamin B2 (mg)0,151,0
Niacin (mg)16,7
Vitamin B6 (mg)0,0750,50
Folic acid (µg)960
Pantothenic acid (mg)0,453
Vitamin B12 (µg)0,32
Biotin (µg)2,215
Choline (mg) 1067
Fe (mg)1,28
I (mg)15100
Cu (mg)0,060,4
Zn (mg)0,755

1. The method of obtaining a mixture of oligosaccharides from milk of animals that have the same range of oligosaccharides that the milk from which it was obtained, comprising the following stages:
(a) concentration deproteinizing milk material to the total solids content from 50 to 75%, provided that the temperature does not rise to a level that can occur hydrolysis or desialylation oligosaccharides;
(b) exposure to concentrated milk material stage partial removal of lactose to obtain a solution having a ratio of lactose: oligosaccharides of less than 250, and
(C) the demineralization of milk material, and the stage of demineralization is carried out either at the stage of concentration, or after the stage of removal of lactose.

2. The method according to claim 1, wherein stage (b) includes a step of crystallization of the lactose and the stage of concentration to remove crystals of lactose and half the treatment solution, with the ratio of lactose: oligosaccharides of less than 250.

3. The method according to claim 1, wherein stage (b) comprises spray drying deproteinizing dairy material and the subsequent addition of water to dissolve oligosaccharides with simultaneous removal of lactose in crystalline form.

4. The method according to any of the preceding claims 1 to 3, in which deproteinizing dairy material is an ultrafiltrate of milk or whey ultrafiltrate.

5. The method according to claim 1, in which stage the removal of lactose is repeated one or more times, followed by concentration of the solution and removal of lactose.

6. The method according to claim 1, further comprising processing liquid product after stage (b) an isolated protease and/or combinations thereof for splitting the residual milk proteins and peptides to compounds with lower molecular weight.

7. The method according to claim 1, further comprising the processing of dairy material β-galactosidase with obtaining serum material containing β-galactosylceramide.

8. The method according to claim 1, further comprising processing liquid product β-galactosidase with obtaining a solution containing β-galactosylceramide.

9. The method according to claim 7 or 8, in which the used β-galactosidase isolated from Aspergillus oryzae.

10. The method according to claim 1, optionally in the with spray drying of liquid product to obtain a powder.

11. The mixture of oligosaccharides obtained by the method according to any one of claims 1 to 10 from the milk of animals, in which the mixture has a ratio of lactose: oligosaccharides of less than 250 and contains the same spectrum of oligosaccharides that the milk from which it was received.

12. The mixture of oligosaccharides according to claim 11, in which the mixture has a ratio of lactose : oligosaccharides from 125 to 1.25.

13. The mixture of oligosaccharides according to claim 11 or 12, which is obtained from the milk of one or more species of animals - cow's milk, goat's milk or Buffalo milk.

14. The mixture of oligosaccharides according to claim 11 also containing β-galactooligosaccharide.

15. The mixture of oligosaccharides according to 14, in which the ratio of oligosaccharide: β-galactooligosaccharide is from 0.01 to 99.

16. The mixture of oligosaccharides on 14 or 15, in which the ratio of oligosaccharide: β-galactooligosaccharide is from 1:2 to 1:20.

17. A food product containing a mixture of oligosaccharides according to any one of § § 11-16.

18. Food product 17, which is a product of or formula for infants.



 

Same patents:

FIELD: medicine.

SUBSTANCE: method of antigen immunogenicity regulation includes incorporation of antigen into structure of immunostimulating complex (TI-complex) - antigen carrier. As protein antigen used is porin from Yersinia pseudotuberculosis, its carrier being immunostimulating complex in form of ultramicroscopic tubules (TI-complex), which consists of mixture of triterpene glycoside cucumarioside A2-2 (CD), cholesterol and polar lipid of monogalactosyldiacylglyceride (MGDG) from marine macrophytes with weight ratio CD:cholesterol:MGMD 6:2:4. Variation of lipid antigen surrounding is achieved due to application of MGDG with various fatty acid composition, separated from various species of marine macrophytes.

EFFECT: method makes it possible to carry out targeted regulation of immune response to antigen not only due to change of quantitative but also qualitative composition of the complex, and obtain new optimal means of specific prevention against causative agents of pseudotuberculosis and other infectious diseases.

3 cl, 6 dwg, 2 tbl, 6 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: claimed invention relates to antithrombotic compound of formula (I) (oligisaccaride-spacer-A(I)), where oligosaccharide is negatively charged pentasaccharide residue of formula given lower, where R5 - OCH3 or OSO3-, charge is compensated by positively charged counterions, and where pentasaccharide residue is obtained from pentasaccharide which has AT-III mediated anti-Xa activity per se; spacer is, in fact, pharmacologically inactive movably bound residue, which has from 10 to 50 atoms long chain; A is residue of -CH[NH-SO2-R1] [CO-NR2-CH(4-benzamidin)-CO-NR3R4], where R1 - 4-methoxy-2,3,6-trimethyphenyl; R2 - H; NR3R4 is piperidinyl group or its pharmaceutically acceptable salt or derivative, where amino group of amidin residue is protected by hydroxyl or (1-6C) alcoxycarbonyl group; where spacer of formula I compound contains one covalent bond with biotin residue of formula -(CH2)4-NR-BT, where R - H or (1-4C)alkyl and BT is residue . Invention also relates to pharmaceutical composition based on formula I compounds for treatment or prevention of thrombosis or other connected with thrombin diseases.

EFFECT: elaboration of antithrombotic compound for treatment or prevention of thrombosis or other, connected with thrombin diseases.

6 cl, 3 tbl, 2 dwg, 3 ex

FIELD: chemistry.

SUBSTANCE: invention refers to sulphated oligosaccharides of the general formula X-[Y]n-Z-UR1, where X, Y and Z each are the same hexose monosaccharide fragment selected out of group including glucose, mannose, altrose, allose, talose, galactose, idose and gulose, adjoining monosaccharide fragments are bound in 1→2, 1→3, 1→4, and/or 1→6 pattern by glycoside bonds, and each carbon atom not binding X, Y and Z groups is bound by single bond with UR group, with exception for carbon atom in 1 position of Z monosaccharide, to which UR1 group is bound by single bond; where n is an integer within 0 to 6; U is O atom or NH; each R is independently C2-C6-alkenyl, benzyl, SO3M or H, where M is any pharmaceutically acceptable cation of alkali metal or organic amine, or R form N3 together with U; R1 is C1-C12alkyl, benzyl, PEG monomethyl ether or its derivative, C1-C12alkylazide, , or , in the form of ester, free acid, free base or hydrate. Also invention refers to pharmaceutical or veterinary composition based on claimed compounds, for disorder prevention or treatment for mammals in case of proliferate retinopathy, solid tumour and/or metastasis result, coagulation/thrombosis and/or virus infection of organism. Additionally invention refers to application of claimed compounds in medicine production for disorder prevention or treatment for mammals in case of proliferate retinopathy, solid tumour and/or metastasis result, coagulation/thrombosis and/or virus infection of organism.

EFFECT: increased efficiency of compound application in medicine.

11 cl, 3 tbl, 1 dwg, 16 ex

FIELD: chemistry.

SUBSTANCE: invention pertains to modified polysaccharide in particular to modified polysaccharide Neisseria meningitidis of serogroup A, which preserves immunogenicity, but has improved stability. The modified polysaccharide is obtained from reaction of capsular polysaccharide, or its fragment - oligosaccharide, with CDI type bifunctional reagent, accompanied by reaction with an amino-compound, such as dimethylamine. Description is also given of modified polysaccharide conjugates and vaccines, which are obtained from such conjugates.

EFFECT: obtaining modified saccharide.

70 cl, 17 dwg

FIELD: chemistry.

SUBSTANCE: claimed invention relates to new oligosaccharides modified with fluorophorous marker, namely, 4-O-methylumbelliferyl β-D-xylopiranosil-(1,4)-bis-[O-β-D-xylopiranosil-(1,4)]-β-D-xylopiranoside, 4-O methylumbelliferyl β-D-xylopiranosil-(1,4)-tris-[O-β-D-xylopiranosil-(1,4)]-β-D-xylopiranoside, 4-O-methylumbelliferyl β-D-xylopiranosil-(1,4)-tetrakis-[O-β-D-xylopiranosil-(1,4)]-β-D-xylopiranoside. It is intended for measuring activities of both pure and coarse preparations of β-xylanases. The invention also relates to fermentative synthesis of oligosaccharides with formula: , which lies in incubation of β-xylosidase from Aspergillus sp. at 37°C in neutral reaction medium in presence of aryl-β-D-xylopiranoside and 4-O-methylumbelliferyl-β-D-xylopiranoside.

EFFECT: possibility to measure activities of both pure and coarse preparations of β-xylanases.

4 cl, 1 dwg, 2 tbl

Carrier of antigens // 2322259

FIELD: biotechnology, immunology.

SUBSTANCE: invention proposes a carrier of antigens as a lipid complex consisting of glycoside, cholesterol and lipid. As glycoside a carrier comprises holotoxin A1, and as lipid - monogalactosyldiacyl glycerides (MGDG) of sea macrophytes taken in the weight ratio 3 (holotoxin A1) : 2 (cholesterol) : (2-6) (MGDG). Prepared glycoside-cholesterol-lipid carrier shows stretched threadlike-tubular structure. Use of the prepared carrier of antigens allows enhancing the immunogenic activity of vaccine preparations, and to decrease or remove completely hemolytic toxicity of holotoxin A1, and to eliminate inflammatory, painful, toxic and hemolytic effects of vaccines.

EFFECT: improved and valuable medicinal properties of carrier and vaccines.

4 dwg, 11 ex

FIELD: biotechnology.

SUBSTANCE: invention relates to carriers of antigens. Proposed carrier represents lipid-saponin complex consisting of a mixture of triterpene glycoside, cholesterol and glyceroglycolipid. Cucumarioside A2-2 is used as triterpene glycosides, and monogalacosyldiacylglycerides of sea macrophites are used as glyceroglycolipids. Method involves mixing solutions of cholesterol and glyceroglycolipid in chloroform, evaporation of mixture until dry under vacuum, addition of 3 weight parts of 0.4% aqueous solution of cucumarioside. Then the mixture is solubilized and the total concentration of cholesterol and glyceroglycolipid is brought about to 2 mg in 1 ml of suspension with phosphate-saline buffer at pH 7.2 followed by sonication of the prepared suspension by ultrasonic oscillation device at frequency 20 kHz for 5 min. Method provides preparing the effective adjuvant form of the carrier.

EFFECT: improved preparing method of carrier.

6 cl, 8 dwg, 13 ex

FIELD: organic chemistry, chemical technology, medicine, pharmacy.

SUBSTANCE: invention describes a novel pentasaccharide conjugate of the formula (I):

wherein R represents independently -SO-3 or -CH3; insert represents a flexible insert of length 13-25 atoms. Charge of a pentasaccharide residue is equilibrated with positively charged counterions and the total amount of sulfate groups in a pentasaccharide residue is 4, 5 or 6. Also, invention relates to a method of its preparing and pharmaceutical composition based on thereof and used in treatment of diseases mediated or associated with thrombin.

EFFECT: improved preparing method, valuable medicinal properties of conjugate.

9 cl, 2 ex

The invention relates to a carbohydrate derivative of the formula (I), where R1represents (1-4C)alkoxy; R2, R3and R4independently represent (1-4C)alkoxy or OSO3-; the total number of sulfate groups is 4-6; and their pharmaceutically acceptable salts

FIELD: medicine.

SUBSTANCE: invention is referred to the area of medicine, namely to hematology, endocrinology and cardiology and can be used for decease of spontaneous RBC aggregation in patients with abdominal obesity. To do that the metformin infusion are performed with the background of hypocaloric diet and dosed static and dynamic physical exercises. Physical exercises include morning hygiene gymnastics, therapeutic gymnastics, single physical exercises during the day, daily swimming for no less than 30 minutes a day in the middle of the day. Metformin is given in the dose 500 mg twice a day. The treatment shall be performed for 1 month.

EFFECT: method provides for normalization of spontaneous RBC aggregation within 1 month, bringing it down on the level close to that in healthy people and thus decreasing the risk of thrombotic complications in patients with abdominal obesity.

2 ex, 1 dwg

FIELD: food industry.

SUBSTANCE: this invention covers food for 0-36 month aged infants. A composition comprising free amino acids as a single source of protein, source of fat acids comprising long-chain polyunsaturated fatty acids (LCPUFA), source of carbonhydrates comprising assimilable and non-assimilable carbonhydrates and bifidus bacteria was proposed for treatment of the patients suffering from tormina, astriction, snivel, sniffle, vomit, diarrhea, feces cruentae, mucus in defecation, spots, eczema, gastroesophageal reflux, eosinophilic esophagitis or asthma, allergy for cow milk and/or intolerance to dietary protein, and/or infections. Herewith, non-assimilable carbonhydrates are chosen from milk protein-free source, and bifidus bacteria are dietary protein-free, and the whole composition is essentially intact protein-free. Besides, assimilable carbonhydrate component contains less than 2 mass percent of lactose from overall assimilable carbonhydrates. Fat component includes 0.1-5 mass percent of LCPUFA from overall fat acids content. As an alternative, this composition is applied for stimulation of immune system maturation of the infants suffering from atopic diseases.

EFFECT: improvement of infant health without risks of adverse allergic reaction.

25 cl, 2 dwg, 3 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to gynaecology, and can be used for treating hyperplastic endometrial processes in patients with metabolic syndrome. A method involves enzyme immunoassay of blood serum to determine a progesterone level, and if its concentration is 8.0 nmol/l and higher, metabolic therapy including administration of methphormin 1000 mg × 2 times a day, hypo-calorie diet with calorage limited to 1500 kcal a day and increased physical activity in the form of intensive walking. The progesterone concentration lower than 8.0 nmol/l requires additionally another enzyme immunoassay of blood serum to evaluate a leptin level, and if its value is lower than 57.18 ng/ml, the metabolic therapy described above is prescribed. If the leptin level exceeds 57.18 ng/ml, the patients require a combined metabolic and hormonal therapy consisting in administration of methphormin 1000 mg × 2 times a day, dufaston 10 mg × 2 times a day starting with the 16th for 25th day of a menstrual cycle, hypo-calorie diet with calorage limited to 1500 kcal a day and graduated physical activity in the form of walking starting with 10 minutes to be gradually increased to 40 minutes in day.

EFFECT: method allows preserving the reproductive function.

1 dwg, 3 ex

FIELD: medicine.

SUBSTANCE: invention relates to feeding of newborn babies delivered by Caesarian section. Claimed is change of composition which contains long-chain polyunsaturated fatty acid and, at least, one substance, selected from group, consisting of (a) nucleotide and (b) nucleotide precursor, selected from group consisting of nucleotides, purine bases, pyridine bases, ribose and deoxyribose for obtaining composition for introduction to newborn baby delivered by Caesarian section, for treatment and/or prevention of infection, diarrhea, intestine phlegmon, allergy, atopic eczema, asthma, allergic rhinitis and/or allergic conjunctivitis. Composition can also be used to improve intestinal maturation, reduction of intestinal permeability and/or for treatment of disorders associated with intestinal barrier, in newborn baby delivered by Caesarian section. Introduced to newborn baby composition is not human breast milk.

EFFECT: invention makes it possible to improve intestinal flora of newborn babies, delivered by Caesarian section.

12 cl, 5 tbl, 6 ex

FIELD: food industry.

SUBSTANCE: invention relates to a non-allergenic food product. The food product includes an amino acid fraction containing at least one component chosen from the group consisting of amino acids and peptides with a degree of polymerisation 7 or less, and a lipid fraction containing at least one fatty acid chosen from the group consisting of arachidonic acid and docosahexanoic acid. The composition content of protein and other peptides with molecular weight 1000 daltons or more (in relation to dry weight) is less than 0.01 wt %, preferably - no less than 0.001 wt %, more preferably - no less than 0.0001 wt %. The food product is used for allergy diagnostics.

EFFECT: invention allows to produce a product which does not impart allergic reactions and is able to attenuate intensity of the patients' allergic reactions.

7 cl, 4 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to therapy, reflexology. Method includes introduction of low-calorie diet. Simple carbohydrates are limited to 10% of calorie content, general fats - to 30-35% of calorie content, animal fats - to 10%. Diet is enriched with proteins to 25%, vitamins, minerals, with magnesium - to 500 mg, cellulose - to 30 g. If body weight index is 25-30 units, food calorie content is limited to 1800 kcal per day for men and 1500 kcal - for women, course of auricular acupuncture is carried out. Course includes carrying out 10 sessions for 30 minutes in points AP 17 and AP 18. If body weight index is higher than 30, food calorie content is limited to1500 kcal for men and 1400 kcal - for women. Additionally to auricular acupuncture after 20-30 days carried out are 10 30-minute long procedures of corporal acupuncture every second day or daily. Corporal acupuncture is performed in points of intersection of anterior, medial and posterior axillary lines with horizontal line, drawn through crests of iliac bones.

EFFECT: method ensures body weight correction without application of drug therapy, does not have side effects.

2 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to hematology and cardiology, and can be used for reduction of spontaneous aggregation of erythrocytes in case of arterial hypertension with dyslipidemia and disturbance of tolerance to glucose. For this purpose at the background of hypolipidemic diet, dosed static and dynamic physical exercise and daily swimming for not less than 30 minutes per day in the middle of the day introduced are lisinopril and metformin. Physical exercise includes morning hygienic gymnastics, therapeutic-preventive gymnastics, fractional physical exercise throughout the day. Lisinipril is introduced in dose 10 mg 1 time per day in the morning. Metformin is introduced in dose 500 mg 2 times per day. Treatment is carried out for 2 months.

EFFECT: method makes it possible to normalise spontaneous aggregation of erythrocytes during 2 months, bringing it to the level close to the level of healthy people, which in its turn contributes to reduction of risk of thrombotic complications.

1 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to hematology and cardiology, and can be used for reduction of spontaneous aggregation of erythrocytes in case of arterial hypertension with abdominal obesity and disturbance of tolerance to glucose. For this purpose at the background of hypocalory diet, dosed static and dynamic physical exercise and daily swimming for not less than 30 minutes per day in the middle of the day introduced are lisinopril and metformin. Physical exercise includes morning hygienic gymnastics, therapeutic-preventive gymnastics, fractional physical exercise throughout the day. Lisinipril is introduced in dose 10 mg 1 time per day in the morning. Metformin is introduced in dose 500 mg 2 times per day. Treatment is carried out for 2 months.

EFFECT: method makes it possible to normalise spontaneous aggregation of erythrocytes during 2 months, bringing it to the level close to the level of healthy people, thus contributing to prevention of vascular complications in patients with arterial hypertension with abdominal obesity and with disturbance of tolerance to glucose.

2 ex

FIELD: food industry.

SUBSTANCE: present invention relates to a food additive to be administered to children. Alternatively, the food additive contains a protein source, a source of vitamins and minerals, a carbohydrates source as well as a lipids source including a source of docosahexaenoic acid, linoleic and linolenic acids. The ratio of ω-6:ω-3 fatty acids in the said food additive is 6:1 or less. Alternatively, the food additive contains protein, carbohydrate and lipid components; the lipid component includes 10% - 50% of canola oil, 5% - 40% of soybean oil, 5% - 40% of high-oleic sunflower oil, 5% - 40% of middle chain triglyceride oil, 1% - 20% of corn oil and 0.1% - 10% of a docosahexaenoic acid source.

EFFECT: food additive having a ratio of ω-6:ω-3 of fatty acids 6:1 and less improves the immune system functions, the heart-vascular system activity, bone tissue quality and has a favourable effect on mental processes.

14 cl, 9 tbl, 3 ex

Ketogenic diet // 2433748

FIELD: food industry.

SUBSTANCE: invention relates to food industry, in particular, to a food product which may be used in ketogenic diet. One proposes a solid or semisolid nutritive composition including proteins, lipids and digestible carbohydrates. The components are produced of at least two different sources; the composition formula ensures 2520-3080 kilojoules per 100 g of dry substance. Lipids weight ratio to the sum total of proteins content and digestible carbohydrates is 2.6-3.8 to 1. The composition may be dissolved in water to produce a liquid food product.

EFFECT: invention allows to produce a product having a high level of ketogenic components applicable for feeding infants suffering from epilepsy.

14 cl, 1 tbl, 2 ex

FIELD: food industry.

SUBSTANCE: invention is related to dairy industry. The sterilised dairy product based on goat milk for pregnant and nursing women alimentation contains initial ingredients such as (wt %): normalised goat milk with fat content equal to 2.5% or 2.45% (91.0-95.0), lactulose with weight fraction of dry substances equal to 55% or 95% (0.7-1.35), omega -3 long chain polyunsaturated fatty acids concentrate (0.098-0.12), corn oil (1.1-1.3), vitamins, biotin, inosite, mineral substances and water.

EFFECT: invention allows to increase nutritional value of the product, improve its quality and preventive properties.

9 ex

Up!